1.Factors Influencing Conflicts of Chemotherapy Decision Making among Pre-Operative Cancer Patients.
Asian Oncology Nursing 2017;17(2):69-78
PURPOSE: This study was attempted to grasp the factors affecting the decision-making conflicts of preoperative cancer patients. METHODS: The subjects of this study were 110 cancer patients scheduled to undergo surgeries at K university hospital. Data were collected utilizing scales for decision-making conflicts and anxiety state, and measurement tools for attitude toward treatment and, shared decision-making. RESULTS: The level of decision-making conflicts over cancer treatment of preoperative cancer patients turned out to be slightly lower than the median. There were significant correlations between shared decision-making between physicians and patients, and quality of life which was a subdomain of attitude toward treatment. In multiple regression analysis, the most powerful predictor was the shared decision-making of physicians and patients. Overall, the explanatory power of the measured variables for decisionmaking conflicts about cancer therapy was 20%. CONCLUSION: The study highlights the importance of shared decision-making and quality of life which involves attitude toward treatment. Thereby, it is deemed to be necessary to develop intervention strategies regarding decision-making conflicts about cancer treatment in consideration of these variables.
Anxiety
;
Decision Making*
;
Drug Therapy*
;
Hand Strength
;
Humans
;
Quality of Life
;
Weights and Measures
2.Hepatic rickets in infancy with neonatal hepatitis.
Mi Koo KANG ; Eun Young CHO ; Soo Jong HONG ; Ki Soo KIM ; Young Seo PARK ; Hyung Nam MOON ; Chang Yee HONG
Journal of the Korean Pediatric Society 1992;35(4):527-533
No abstract available.
Cytomegalovirus
;
Hepatitis*
;
Rickets*
3.A clinical observation on meconium peritonitis.
Ki Soo KIM ; In Koo KIM ; Nyung Nam MOON ; Chang Yee HONG ; Jung Hwan CHOI ; Jeong Kee SEO ; Chong Ku YUN ; Kwi Won PARK ; Woo Ki KIM
Korean Journal of Perinatology 1992;3(1):42-50
No abstract available.
Meconium*
;
Peritonitis*
4.Treatment of Kaeasaki disease with single high-dose intravenous gammaglobulin.
Mi Koo KANG ; Eun Young CHO ; Young Hwue KIM ; Ki Soo KIM ; Young Soo PARK ; In Sook PARK ; Hyung Nam MOON ; Chang Yee HONG
Journal of the Korean Pediatric Society 1992;35(3):342-348
No abstract available.
Mucocutaneous Lymph Node Syndrome
5.Epidemics of aseptic meningitis in Seoul area during 1989-90.
Eun young CHO ; Mi Koo KANG ; Soo Jong HONG ; Ki Soo KIM ; Young Seo PARK ; In Sook PARK ; Hyung Nam MOON ; Chang Yee HONG
Journal of the Korean Pediatric Society 1991;34(11):1565-1572
No abstract available.
Enterovirus
;
Meningitis, Aseptic*
;
Seoul*
6.Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19:Real-World Data during the Delta Variant Predominance
Yee Gyung KWAK ; Je Eun SONG ; Jieun KANG ; Jiyeon KANG ; Hyung Koo KANG ; Hyeon-Kyoung KOO ; Hye Kyeong PARK ; Sang Bong CHOI ; Hyuk Pyo LEE ; Myung Jin LEE ; Baek-Nam KIM
Infection and Chemotherapy 2022;54(4):781-786
Regdanvimab is the only monoclonal antibody available in Korea that targets severe acute respiratory syndrome coronavirus 2. We retrospectively evaluated the clinical characteristics of 374 adults hospitalized with coronavirus disease 2019 (COVID-19) who were treated with regdanvimab from September through December 2021. In total, 322 (86.1%) patients exhibited risk factors for disease progression. Most patients (91.4%) improved without additional treatment. No patient died or was transferred to intensive care. This study shows that regdanvimab prevented disease progression in high-risk patients with mild to moderate COVID-19 infections during Delta variant predominance.
Result Analysis
Print
Save
E-mail